Cure My Disease

Don't miss your cure!

 Log in / Sign up

Home c-peptide tests could reveal hidden insulin production in diabetes

NCT ID NCT07828626

Knowledge-focused Sponsor: Royal Devon and Exeter NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers want to learn how the body's own remaining insulin production, measured by a marker called C-peptide, affects quality of life and health outcomes in people with insulin-treated diabetes. The study follows about 700 adults, including some from a previous diabetes study, and asks them to provide blood samples, including simple finger-prick tests at home after meals. The goal is to find out which C-peptide measurements best predict blood sugar control and wellbeing, so doctors can use the most practical tests in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the study identifies which C-peptide tests best predict blood sugar control and wellbeing, doctors could use simpler home tests to tailor diabetes care and better identify who still makes some insulin.
What could go wrong
This is an observational study, so it cannot prove that C-peptide levels cause better outcomes. The findings may not apply to all people with diabetes, and home tests may not match lab results closely enough to be useful.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 700 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

ARM 1: Participants who have previously taken part in the StartRight study (NCT03737799) with consent to re-contact for future research (from sites across the United Kingdom (UK)). ARM 2: Participants who have previously taken part in the StartRight study or other diabetes research cohorts, as well as patients referred by their clinician or self-referred (across the UK).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

ARM 1 Inclusion Criteria: * Previously recruited to the StartRight study (NCT03737799) with consent to be contacted for further research * Clinical diagnosis of diabetes \& Insulin treated * Able and willing to provide informed consent/assent. * Aged 18 years or older. ARM 2 Inclusion Criteria: * Clinical diagnosis of Type 1 diabetes * Known C-peptide, measured as part of previous research or as part of diabetes clinical care OR Where C-peptide is not measured, participant must be within 7 years of diagnosis and have at least 1 positive islet antibody, measured at any time since diabetes diagnosis. * Where measured C-peptide is \>600pmol/L, previous positive islet autoantibodies. * Able and willing to provide informed consent * Aged 18 years or older Exclusion Criteria: \- Renal failure defined by eGFR \<30mL/min/1.73 m²

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes Diabetes (DM) Diabetes (insulin-requiring, type 1 or type 2) Type 1 diabetes (T1D)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinical Research Centre

    RECRUITING

    Bristol, BS10 5NB, United Kingdom

  • D1 Wolfson Centre Research and Development

    RECRUITING

    Bath, BA1 3NG, United Kingdom

  • Diabetes and Endocrine Centre

    RECRUITING

    Truro, Cornwall, TR1 3LJ, United Kingdom

  • NIHR Exeter Clinical Research Facility

    RECRUITING

    Exeter, Devon, EX2 5DW, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.